Neuroscience is arguably the next great frontier in medicine and 2022 dawned with a wave of exhilarating progress for the neurodegenerative drug development community.
Eli Lilly is investing $700M into genetic medicine, announcing plans to establish a Boston research center, and with the acquisition of Prevail Therapeutics in late 2020, Lilly secured access to two gene therapies that had already advanced into human testing — with one targeting Parkinson’s disease and the other, dementia.
A startup led by Novartis veteran raises $80 million to develop treatments for people with degenerative brain conditions. AviadoBio will move its lead experimental program, for frontotemporal dementia, into human testing. The company will also use funds to advance work on preclinical therapies, including one for amyotrophic lateral sclerosis (ALS).
Our 2022 program has been created and tailored to explore a whole host of brand-new topics including learning how to tailor your regulatory drug development approach for swift approvals, dissecting the neurodegenerative drug development investing landscape and uncovering the potential of precision neurology.
Join us in progressing the pipeline in rare neurodegenerative diseases as a model to expand into broader indications for your team to get up to speed with the insights they need to accelerate their neurodegenerative drug development.
Unite with 50+ experts from industry-leading companies to uncover the secrets behind developing industry-defining rare and genetic neurodegenerative therapies; tailor the experience to meet your needs and supercharge your neurodegenerative drug development strategy.
Download the full event guide for the speaker faculty and session details.
Early Bird & Team Discounts available – Secure your place today
The post Welcome to 1st Rare & Genetic Neurodegenerative Drug Development Summit appeared first on .
